Respiratory distress syndrome (RDS) is the most common respiratory morbidity in very low birth weight (VLBW) preterm infants. Surfactant therapy is the standard care for infants with RDS. Natural surfactants appear to be better than synthetic surfactants for RDS treatment. Lung injury remains an important cause of morbidity among VLBW infants despite current treatments. Barotrauma, volutrauma or oxygen-induced lung inflammation contributes to the development of bronchopulmonary dysplasia (BPD). Observational studies using noninvasive ventilation, such as, nasal continuous positive pressure (NCPAP) show a decrease in BPD when used to avoid intubation or minimize the duration of mechanical ventilation via endotracheal tube. Recently, nasal intermittent positive pressure ventilation (NIPPV) has been shown to decrease post-extubation failures significantly compared to NCPAP and has demonstrated a trend toward reduced risk of BPD. The administration of early surfactant followed by noninvasive ventilation has also been shown to improve pulmonary outcomes.
Introduction
Incidence of prematurity continues to increase in spite of major advances in perinatal care, especially in developed countries. The most recent data shows 12.7% rate of preterm births in United States. 1 Prematurity is now the number one cause of infant mortality accounting for 34.3% of all infant deaths in 2002, 2 contributing significantly to neonatal morbidity and mortality. Respiratory distress syndrome (RDS) occurs in nearly 50% of very low birth weight (VLBW) infants (less than 1500 g). 3 Surfactant therapy has become the standard of care in preterm infants with RDS and is associated with a decrease in pneumothorax, neonatal mortality and increased survival without bronchopulmonary dysplasia (BPD). The timing of surfactant administration is also crucial as evidence points to better outcomes with early administration in addition to noninvasive ventilation.
Noninvasive ventilation may be administered using either nasal continuous positive pressure (NCPAP) or nasal intermittent positive pressure ventilation (NIPPV) each of which has its advantages and disadvantages. A variety of devices utilizing various interfaces for delivery of CPAP to neonates are available.
Bronchopulmonary dysplasia BPD remains a major morbidity among surviving VLBW infants despite surfactant therapy and advances in mechanical ventilation. BPD is associated with both short-and long-term adverse pulmonary and neurodevelopmental outcomes. Surfactant deficiency is one aspect of the multifactorial nature of BPD. Barotrauma or volutrauma and oxygen-induced lung inflammation are thought to contribute to the development of BPD. Clinical BPD, defined as the need for supplemental oxygen exactly at 36 weeks postmenstrual age (PMA) is around 35% among infants with a birth weight of less than 1250 g. 4 The reported incidence of BPD also varies among different Newborn Intensive Care Units (NICU), based on different criteria for oxygen administration between physicians. To standardize BPD incidence, a physiological definition of BPD, based on a timed room-air challenge at 36±1 weeks PMA in selected preterm infants has been proposed. 4 Preterm infants on mechanical ventilation or requiring greater than 30% oxygen to maintain oxygen saturation between 90 and 96% were considered to have 'physiological BPD'. Infants receiving less than or equal to 30% oxygen or effective oxygen greater than 30% with saturations greater than 96% were given room-air challenge for 30 minutes. Infants in whom saturations decreased to less than 90% were considered to have 'physiological BPD.' The physiologic definition of BPD reduced the overall incidence of BPD by 10%. However, differences in BPD incidence remained even with the use of standardized definition of BPD.
Surfactant therapy
Natural, modified surfactants derived from animal sources as well as synthetic surfactants that are devoid of surfactant-associated proteins (SP) have been extensively studied. Fourteen comparative trials using different natural and synthetic surfactants have been published. 5 To date, treatment with natural surfactants has been shown to be associated with better clinical outcomes during the acute phase of RDS when compared to synthetic surfactants. However, the incidence of BPD is not different in infants treated with either natural or synthetic surfactants. In the only trial that compared two different synthetic preparations, namely, colfosceril palmitate (Exosurf; Research Triangle Park, NC, USA) and lucinactant (Surfaxin, Discovery Laboratories, Doylestown, PA, USA), BPD was significantly lower (40.2 versus 45%, P ¼ 0.045) with lucinactant. 6 However, comparisons of lucinactant with natural surfactants, beractant (beractant, Ross Products Division, Abbott Laboratories Inc., Columbus, OH, USA) and poractant alfa (Curosurf; DEY LP, Napa, CA, USA) showed no significant differences in the occurrence of BPD between these preparations. 6, 7 Both of these studies had methodological problems, however, and did not address the question of superiority of synthetic surfactant over natural surfactants. 8 The primary reason for the superiority of natural surfactants is owing to the presence of surfactant proteins B and C. The trial conducted by Moya et al. 6 involving lucinactant had three arms, and randomized preterm infants to lucinactant, colfosceril palmitate and beractant. Infants receiving lucinactant had less RDS and less BPD in this prophylaxis trial than those receiving colfosceril palmitate, but not less than those receiving beractant. The trial conducted by Sinha et al. 7 had two groups, comparing lucinactant with poractant alfa. No differences were found in the incidence of RDS, mortality or BPD between these two preparations. However, there were some major problems with both of these studies. Both studies were designed as 'noninferiority' studies. The Moya et al. 6 study was underpowered to detect efficacy against beractant. The study by Sinha et al. 7 was stopped owing to slow recruitment of patients after enrolling only 252 of the original calculated sample size of 496 patients, and was also underpowered even to establish equivalency between lucinactant and poractant alfa, let alone superiority. Furthermore, the calculation for sample size Sinha et al. 7 utilized was based on results published in 1988, almost two decades ago. The dose of poractant alfa used in this prophylaxis trial also was not the approved dose for poractant alfa.
Natural surfactants that are available for clinical use differ in their composition, amount of phospholipids (PL), SP, plasmalogens, viscosity and volume of administration. Among the three commonly available natural surfactants, (beractant, calfactant (calfactant, Forest Laboratories, St Louis, MO, USA), and poractant alfa), poractant alfa contains the highest amount of phospholipids distributed in the lowest volume as well as the highest amount of plasmalogens (Table 1) . 9 These characteristics may account for some of the differences seen in comparative trials using different natural surfactant preparations. Beneficial effects of plasmalogens have been studied extensively in cardiovascular and neurological disorders in adults. Plasmalogens are part of structural membrane components, a reservoir for second messengers, and may be involved in membrane fusion and transport. Plasmalogens may also function as antioxidants, thus protecting cells from oxidative stress. Higher plasmalogen content in the tracheal aspirate fluid at birth in preterm infants has been shown to be associated with a decreased risk of subsequent development of BPD. 12 Eight trials comparing different natural surfactant preparations have been published. 5 No difference in BPD was noted in these trials. Two large, but, incomplete trials involving a total of 2,110 preterm infants were published in 2005. 13 Both of these trials were stopped after 32 months owing to slow enrollment of patients. Inadequate sample sizes due to early trial closure prevented the investigators from accepting or rejecting null hypotheses. However, in the prophylaxis study with 749 patients, infants alive with BPD were 34% in the survanta group and 33% in the infasurf group. Similarly, in the rescue trial, the proportion of infants alive with BPD was identical, at 31% in survanta-and infasurf-treated patients. Timing of surfactant administration has also been shown to impact the overall incidence of BPD. Earlier administration of surfactant is associated with improved outcomes compared to delayed treatment. However, pre-ventilatory, 'prophylactic' surfactant therapy in a fluid-filled lung has not been shown to offer any advantages over post-ventilatory, early rescue surfactant administration.
14 Clearly, early rescue administration of surfactant after initial stabilization and resuscitation of the preterm infant with RDS is better than delayed administration.
Noninvasive ventilation
Observational studies have shown that early surfactant administration followed by extubation to noninvasive nasal ventilation such as, NCPAP, NIPPV or NCPAP alone without surfactant therapy decreases the incidence of BPD in preterm infants. Sahni et al. 15 reported a very low incidence of BPD (7.4%) in infants less than 1250 g, primarily managed with 'bubble' NCPAP. Noninvasive ventilation may be applied using CPAP via nasal (NCPAP) or naso-pharyngeal (NP-CPAP) prongs. NCPAP or NP-CPAP is used as a primary mode of treatment of RDS or at extubation to prevent post-extubation failures. NIPPV is a form of noninvasive ventilation that combines NCPAP with intermittent positive pressure ventilation (IPPV) breaths.
CPAP generators
A variety of devices are used to deliver CPAP to neonates. All CPAP systems have three basic components: heated and humidified gas, patient interface and an expiratory valve. Pressure generated at the patient interface is dependent on the flow rates used in all systems, except when using 'bubble CPAP'. The heart of the CPAP device is the expiratory valve, which maintains positive pressure. Currently, expiratory valves are of two types: variable pressure-flow valves and threshold resistors. Variable pressure-flow valves provide a constant resistance to flow. The level of pressure within the system is equal to the product of gas flow through the orifice of the valve and the resistance of the valve (pressure ¼ flow Â resistance). Pressures can fluctuate widely during spontaneous breathing. For instance, when an infant attempts to exhale into a fixed-resistance expiratory valve CPAP, internal pressure will increase significantly, potentially causing barotrauma and increased work of breathing. To deliver stable pressures, new devices, such as, infant flow drivers with 'fluidic flip' mechanisms have been developed. Several studies have compared the interface method of CPAP and found no difference in clinical outcomes when applying CPAP with the infant flow driver versus a conventional nasal CPAP device. 16 On the contrary, threshold resistors provide a constant level of pressure within the system, independent of flow. This is accomplished by submerging the expiratory limb of respiratory circuit within a fluid column (bubble CPAP). The amount of pressure maintained within the system is simply determined by the depth of submersion, and is independent of flow rate. Furthermore, observational studies have shown 'oscillatory type of ventilation' during bubble CPAP. 17 Morley et al. 18 showed that bubbling rates during bubble CPAP had no effect on ventilation or oxygenation. In some infants on bubble CPAP, chest wall vibrations due to the bubbling of the water column may be seen. Furthermore, noisy pressure waveform of bubble CPAP superimposed on pressure fluctuations promotes airway opening as a result of stochastic resonance. 19 CPAP interface Different types of nasal CPAP interfaces have been used to deliver CPAP. Binasal prongs are more effective than single nasal prongs in preventing post-extubation failures. 20 Nasal cannulae have been used to deliver oxygen at flow rates of 0.5 litre per minute (LPM) to as high as six LPM flow, usually with no intention of delivering CPAP. However, a significant amount of CPAP is generated, and is not measured continuously at the bedside. For example, use of flow rates of two LPM via a nasal cannula with an outer diameter of 3 mm results in a mean CPAP of 9.8 cm H 2 O. 21 Reported complications with the use of high-flow nasal cannula include increased incidence of pneumothoraces, gas trapping, volutrauma, and even perforated ear drum in an infant while on high-flow nasal cannula at a flow rate of 4 LPM (personal communication). One must exercise extreme caution when delivering flow rates greater than 1-2 LPM via nasal cannula. NCPAP or NPCPAP is associated with minor complications, such as nasal excoriation, septal injury, abdominal distention and feeding intolerance. Careful attention at the bedside during NCPAP will minimize these complications.
NCPAP as a primary mode of respiratory support in preterm infants has been successfully used for many years in some centers in United States. Aly et al. 22 in a retrospective study of 234 VLBW infants reported successful implementation of early NCPAP in the delivery room in 64.5% of infants. Success depended on the gestational age of the infants and experience of care providers over time. While evaluating the benefits of prophylactic NCPAP in more mature preterm infants born between 28 and 31 weeks gestation in a multicenter randomized clinical trial, Sandri et al. 23 showed no benefits of prophylactic NCPAP over rescue NCPAP initiated when the oxygen requirements increased to greater than 40%. Recently, use of portable devices, such as Neopuff Infant Resuscitator (Fisher & Paykel Healthcare Corporation Limited, Irvine, CA, USA) to deliver consistent positive end-expiratory pressure in the delivery room and during transport from the delivery room, is gaining popularity. 24 Nasal intermittent positive pressure ventilation One of the major reasons for failure in infants managed with conventional or infant flow NCPAP is owing to recurrent episodes of apnea, bradycardia and/or oxygen desaturations. 16 Addition of backup rate in infants on NCPAP has been shown to decrease the incidence of post-extubation failures significantly. Extubation of VLBW infants to NIPPV resulted in a decreased need for reintubation, [25] [26] [27] and a trend toward lower incidence of BPD in two studies (Table 2) . 26, 27 NIPPV has also been shown to reduce atelectasis, improve ventilation-perfusion matching, and reduce apnea of prematurity. 29 Recently, in a retrospective, case-control study, introduction of NIPPV resulted in a significant decrease in clinical BPD. 30 Within the limits of the small numbers of infants randomized to NIPPV there is a reassuring absence of the gastrointestinal side effects that were reported in previous case studies.
Surfactant therapy and NCPAP
An approach that combines early surfactant administration and early extubation to NCPAP has been evaluated in Europe. Verder et al. 31 conducted a multicenter randomized, controlled trial to determine whether early versus late treatment with poractant alfa and extubation to NCPAP reduced the requirement for mechanical ventilation via endotracheal tube in 60 preterm infants less than 30 weeks gestation with RDS. Infants who received early treatment had improved oxygenation six hours after randomization. The need of mechanical ventilation before discharge was reduced from 68% in the late-treated infants to 25% in the early-treated infants. Dani et al. 32 showed that early poractant alfa administration followed by extubation to NCPAP in infants less than 30 weeks gestational age decreased the need for mechanical ventilation via endotracheal tube to 0% by seven days of age compared to 43% in the mechanical ventilation group. A meta-analysis evaluating the use of surfactant and rapid extubation to NCPAP in somewhat more mature infants has been published. 33 Evidence indicates that infants with RDS treated with early surfactant replacement therapy followed by extubation to NCPAP are less likely to need mechanical ventilation, and experience a decreased incidence of air leaks than infants treated with NCPAP and delayed surfactant therapy.
Conclusion
In summary, the use of noninvasive ventilation as a primary mode or following a brief period of ventilation via endotracheal tube for early surfactant administration is associated with improved outcomes in preterm infants with respiratory distress. Successful application of this noninvasive form of respiratory support depends largely on the gestational age of the infants and staff experience. Short binasal prongs are more effective than single nasal prongs to deliver NCPAP. Addition of backup rate via the nasal prongs (NIPPV) decreases postextubation failure rates and may improve pulmonary outcomes. NIPPV is a useful method of augmenting the beneficial effects of NCPAP in preterm infants with respiratory distress. Currently, multinational studies evaluating NIPPV in preterm infants are on going. 
